KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Accumulated Expenses (2016 - 2025)

Novavax (NVAX) has 16 years of Accumulated Expenses data on record, last reported at $107.2 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 49.25% year-over-year to $107.2 million; the TTM value through Dec 2025 reached $107.2 million, down 49.25%, while the annual FY2025 figure was $107.2 million, 49.25% down from the prior year.
  • Accumulated Expenses reached $107.2 million in Q4 2025 per NVAX's latest filing, down from $115.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $673.7 million in Q4 2021 and bottomed at $86.7 million in Q2 2025.
  • Average Accumulated Expenses over 5 years is $332.7 million, with a median of $284.3 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: surged 15846.18% in 2021, then tumbled 65.27% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $673.7 million in 2021, then fell by 12.26% to $591.2 million in 2022, then tumbled by 33.24% to $394.7 million in 2023, then crashed by 46.5% to $211.2 million in 2024, then crashed by 49.25% to $107.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $107.2 million in Q4 2025, $115.6 million in Q3 2025, and $86.7 million in Q2 2025.